Table 1

Prostate tumor frequency and age of onset in EB 1089- and placebo-treated Gγ/T-15 transgenic mice

TreatmentStart (wk)aNo. of mice% prostate tumorbAvg. age of onsetc (wk)
Placebo1412100 (12/12)19.4 (3.0)
EB 1089
 0.51080 (8/10)18.5 (3.2)
 2978 (7/9)20.4 (2.2)
 31486 (12/14)19.3 (2.4)
 41191 (10/11)18.6 (3.1)
 51377 (10/13)20.2 (3.0)
 10683 (5/6)17.5 (2.0)
Placebo111090 (9/10)18.9 (3.1)
EB 1089
 0.55100 (5/5)16.3 (2.3)
 29100 (9/9)20.1 (3.1)
 311100 (12/12)18.6 (3.2)
 41493 (13/14)18.5 (3.3)
Placebo9989 (8/9)18.1 (2.7)
EB 1089
 21479 (11/14)18.1 (2.9)
  • a Age of Gγ/T-15 mice when treatment began.

  • b Percentage of mice at 24 weeks that developed prostate tumors.

  • c Age of mice when prostate tumors were first detected by palpation. Number in the parentheses is SD. There were no significant differences in % prostate tumor and age of onset between EB 1089- and placebo-treated mice.